Bristol-Myers Squibb (BMY) Stock Overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 6/6 |
Rewards
Risk Analysis
BMY Community Fair Values
Create NarrativeSee what 328 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$65
FV
14.5% undervalued intrinsic discount660
users have viewed this narrative3users have liked this narrative
0users have commented on this narrative
21users have followed this narrative
Bristol-Myers Squibb Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$55.60 |
| 52 Week High | US$62.89 |
| 52 Week Low | US$42.52 |
| Beta | 0.24 |
| 1 Month Change | -0.13% |
| 3 Month Change | -5.68% |
| 1 Year Change | 10.85% |
| 3 Year Change | -13.34% |
| 5 Year Change | -16.92% |
| Change since IPO | 2,502.12% |
Recent News & Updates
Narrative Update • Jun 02
BMY: Late Stage Milvexian Readouts And Pipeline Wins Will Drive Re Rating
Analysts have raised the average Bristol-Myers Squibb price target by a few dollars, citing a series of recent upward revisions into the $60 to $70 range. These revisions reflect ongoing debate around macro risks, healthcare sector positioning, and upcoming Milvexian Phase III data.Seeking Alpha • Jun 02
Bristol Myers Squibb: This Pullback Is A Gift For Long-Term Investors
Summary Bristol Myers Squibb offers a compelling buy-the-dip opportunity with a forward P/E of 8.7x and a 4.6% dividend yield. BMY's diversified growth portfolio posted 9% YoY sales expansion, offsetting legacy drug declines and demonstrating early-stage growth runway. Upcoming pivotal clinical readouts in H2 2026, including milvexian and Cobenfy, are set to define BMY's long-term growth trajectory. Current valuation implies no growth, yet BMY's robust pipeline, strong balance sheet, and dividend growth support a bullish long-term outlook. Read the full article on Seeking AlphaRecent updates
Narrative Update • Jun 02
BMY: Late Stage Milvexian Readouts And Pipeline Wins Will Drive Re Rating
Analysts have raised the average Bristol-Myers Squibb price target by a few dollars, citing a series of recent upward revisions into the $60 to $70 range. These revisions reflect ongoing debate around macro risks, healthcare sector positioning, and upcoming Milvexian Phase III data.Seeking Alpha • Jun 02
Bristol Myers Squibb: This Pullback Is A Gift For Long-Term Investors
Summary Bristol Myers Squibb offers a compelling buy-the-dip opportunity with a forward P/E of 8.7x and a 4.6% dividend yield. BMY's diversified growth portfolio posted 9% YoY sales expansion, offsetting legacy drug declines and demonstrating early-stage growth runway. Upcoming pivotal clinical readouts in H2 2026, including milvexian and Cobenfy, are set to define BMY's long-term growth trajectory. Current valuation implies no growth, yet BMY's robust pipeline, strong balance sheet, and dividend growth support a bullish long-term outlook. Read the full article on Seeking Alpha
Narrative Update • May 18
BMY: Pipeline Execution And Macro Shifts Will Shape Future Risk Balance
Analysts now see Bristol-Myers Squibb’s fair value edging down by $0.08 to $62.96, as they factor in slightly weaker revenue growth and profit margin assumptions alongside a higher future P/E, even as recent Street price target moves reflect mixed views on the stock’s pipeline and macro setup. Analyst Commentary Recent Street commentary on Bristol-Myers Squibb highlights a wide range of views on execution risk, pipeline delivery and how those factors may feed into valuation over the next few years.Narrative Update • May 03
BMY: Upcoming Late Stage Readouts Will Drive Potential Re Rating Opportunity
Analysts have made only a modest adjustment to their Bristol-Myers Squibb outlook, with small changes to revenue and profitability assumptions feeding into updated price targets that cluster in a wide range from about $60 to $75. This reflects differing views on the pipeline and upcoming Milvexian data as potential drivers for the story.Narrative Update • Apr 19
BMY: Pipeline Progress And Sector Shifts Will Shape Future Risk Balance
Analysts have raised the implied fair value for Bristol-Myers Squibb to $63.04 from $59.91, reflecting a series of recent price target increases based on slightly less severe revenue contraction expectations, a modest improvement in projected profit margins, and support from pipeline-related research updates across multiple firms. Analyst Commentary Recent research has focused on how Bristol-Myers Squibb balances patent expirations on key products with progress in its pipeline and late stage programs, and how that mix feeds into valuation, execution risk, and potential growth beyond current revenue headwinds.
Narrative Update • Apr 04
BMY: 2026 Catalyst Calendar Will Likely Fail To Offset Patent Cliff
Analyst price targets for Bristol-Myers Squibb have moved higher into a broad $60 to $75 range, with analysts pointing to a rich 2026 catalyst calendar, emerging pipeline readouts such as milvexian Phase III data, and relatively lower exposure to AI disruption risks as key supports for the updated views. Analyst Commentary Recent research highlights a mix of optimism and caution around Bristol-Myers Squibb, with the Street focusing on a packed 2026 catalyst calendar, milvexian Phase III data, and a broad set of late stage assets.Narrative Update • Mar 21
BMY: 2026 Late Stage Pipeline Catalysts Will Likely Limit Further Upside
The analyst price target for Bristol Myers Squibb has moved higher, with the fair value estimate shifting from $40.67 to $45.67 as analysts point to a richer pipeline of late stage catalysts, a higher projected profit margin, and sector wide support from the appeal of healthcare during a choppy macro backdrop. Analyst Commentary Recent research coverage on Bristol Myers Squibb has tilted more constructive, with several firms lifting price targets into the US$60 to US$75 range and highlighting a dense calendar of late stage readouts through 2026.Narrative Update • Mar 06
BMY: 2026 Late-Stage Pipeline Readouts Will Shape Re-Rating Potential
Analysts have lifted their Bristol Myers Squibb fair value estimate from $68.00 to $75.00, citing higher Street price targets and an increased focus on pipeline catalysts such as the Phase III milvexian data and a dense slate of 2026 readouts. Analyst Commentary Recent Street research on Bristol Myers Squibb clusters around a more constructive view of the pipeline, especially the 2026 readout slate and the Phase III milvexian program, with several firms revisiting their valuation frameworks in light of these potential catalysts.Narrative Update • Feb 20
BMY: 2026 Pipeline Catalysts And Sector Recovery Will Shape Risk Balance
Our analyst fair value estimate for Bristol Myers Squibb has moved modestly higher to about $60. This reflects how recent price target increases and generally constructive research commentary around the pipeline are starting to offset concerns about upcoming patent expirations.Analysis Article • Feb 18
We Like Bristol-Myers Squibb's (NYSE:BMY) Earnings For More Than Just Statutory Profit
Bristol-Myers Squibb Company ( NYSE:BMY ) announced a healthy earnings result recently, and the market rewarded it with...Narrative Update • Feb 06
BMY: 2026 Pipeline Readouts And Sector Recovery Will Guide Next Repricing
Our analyst fair value estimate for Bristol Myers Squibb has moved modestly higher to US$58.13 from US$56.26. This reflects updated Street research in which analysts cite a richer mix of potential 2026 pipeline catalysts and a slightly higher assumed future P/E multiple, both of which support recent price target increases across several firms.Narrative Update • Jan 23
BMY: 2026 Pipeline Readouts Will Likely Cap Near Term Upside
Analysts have lifted their blended price target on Bristol Myers Squibb by roughly US$2 to reflect higher estimated fair value and profitability, citing a rich set of 2026 pipeline readouts and what they view as underappreciated upside in several late-stage assets. Analyst Commentary Recent Street research on Bristol Myers Squibb points to a mixed but generally constructive stance, with several firms lifting price targets into the US$53 to US$65 range and highlighting what they see as meaningful 2026 data catalysts across eight late stage assets.Narrative Update • Jan 08
BMY: Sector Tailwinds And Pipeline Milestones Will Shape Next Share Rerating
Analysts have nudged their price targets for Bristol Myers Squibb higher, with moves such as UBS shifting to a Buy rating with a US$65 target from US$46 and Citi lifting its target to US$53 from US$45. This reflects growing confidence tied to sector tailwinds, improving deal activity, and a refreshed view of the company’s valuation and earnings power.Narrative Update • Dec 25
BMY: Sector Perform View Will Limit Upside Despite Upcoming Earnings Focus
Analysts have nudged their fair value estimate for Bristol-Myers Squibb higher to about $38.41 from $35.86, reflecting a modestly richer future earnings multiple despite slightly weaker near term revenue growth and margin assumptions, and a new $45 price target under a Sector Perform view. Analyst Commentary Recent Street commentary frames Bristol-Myers Squibb as a lagging, but not broken, story within large cap biopharma.Narrative Update • Dec 11
BMY: Sector Outlook And Policy Shifts Will Shape Next Share Rerating
Analysts have nudged their price target for Bristol-Myers Squibb slightly higher to approximately $54 per share. This reflects a modestly richer future earnings multiple despite expectations for somewhat weaker revenue growth and profit margins, along with a more cautious Sector Perform stance from recent Street research.Narrative Update • Sep 04
Aging Demographics And Genomics Will Drive Healthcare Demand
Analysts maintained a cautious outlook on Bristol-Myers Squibb due to muted Cobenfy prescription trends and pipeline execution concerns, partially offset by optimism for upcoming Alzheimer’s data and future optionality, resulting in the consensus price target remaining steady at $53.00. Analyst Commentary Bearish analysts point to recent moderation in Cobenfy prescriptions for schizophrenia and maintain low growth expectations for this indication in the second half of 2025.Shareholder Returns
| BMY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.6% | 4.5% | -4.1% |
| 1Y | 10.8% | 37.3% | 20.6% |
Return vs Industry: BMY underperformed the US Pharmaceuticals industry which returned 37.3% over the past year.
Return vs Market: BMY underperformed the US Market which returned 20.6% over the past year.
Price Volatility
| BMY volatility | |
|---|---|
| BMY Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BMY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BMY's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1887 | 32,500 | Chris Boerner | www.bms.com |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM.
Bristol-Myers Squibb Company Fundamentals Summary
| BMY fundamental statistics | |
|---|---|
| Market cap | US$115.34b |
| Earnings (TTM) | US$7.28b |
| Revenue (TTM) | US$48.48b |
15.6x
P/E Ratio2.3x
P/S RatioIs BMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMY income statement (TTM) | |
|---|---|
| Revenue | US$48.48b |
| Cost of Revenue | US$13.58b |
| Gross Profit | US$34.90b |
| Other Expenses | US$27.62b |
| Earnings | US$7.28b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Jul 30, 2026
| Earnings per share (EPS) | 3.56 |
| Gross Margin | 71.98% |
| Net Profit Margin | 15.01% |
| Debt/Equity Ratio | 221.2% |
How did BMY perform over the long term?
See historical performance and comparisonDividends
4.5%
Current Dividend Yield70%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 15:27 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bristol-Myers Squibb Company is covered by 45 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Charles Butler | Barclays |